RT - European Journal of Gynaecological Oncology ID - 10.31083/j.ejgo.2021.03.2173 T1 - Methylated p16 gene is associated with negative expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in breast cancer A1 - Shun-Li Zhang A1 - Ya-Qi Wang A1 - Jing-Hua Zhang A1 - Ji-Wei Hu A1 - Jie Ma A1 - Zheng Gu A1 - Yu Wang A1 - Jing-Jing Chen K1 - Breast cancer; Methylation; p16 gene; Estrogen receptor; Progesterone receptor; Human epidermal growth factor receptor; Diagnostic value YR - 2021 SP - 530 AB -
Objective: This study was conducted to determine the relationship between p16 gene methylation and expression of relevant receptors in breast cancer (BC) for subtyping the disease. Methods: Methylation-specific PCR (MSP) was carried out to detect the methylation status of p16 gene in 240 tissue samples and 205 serum samples from BC patients treated at our hospital. Immunohistochemistry was used to determine the expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). Receiver operating characteristics (ROC) curve was analyzed for diagnostic value based on methylation status for triple-negative (TN) BC. Results: The overall methylation rates of the p16 gene were 36.7% (88/240) and 35.1% (72/205) in the tissue and serum samples, respectively. In patients with ER, PR and HER2-TNBC, the methylation rate of the p16 gene was significantly higher than that in non-triple negative patients (84.9%, 62/73) vs (25.9%, 35/135, P